<DOC>
	<DOCNO>NCT00817765</DOCNO>
	<brief_summary>The purpose study determine influence posaconazole unboosted fosamprenavir pharmacokinetics , vice versa , healthy volunteers.A second objective determine safety combine use fosamprenavir posaconazole healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study Posaconazole Boosted Fosamprenavir</brief_title>
	<detailed_description>Infections fungi yeast frequently occur patient infected human immunodeficiency virus type 1 ( HIV-1 ) . Fosamprenavir PI use treat HIV-infection combination ritonavir . Once hydrolyzed amprenavir , substance substrate CYP3A4 . Ritonavir extremely potent inhibitor CYP3A4 serve booster pharmacokinetics amprenavir . Posaconazole potent CYP3A4 inhibitor therefore might enhance amprenavir pharmacokinetics similar way ritonavir . The current study design test hypothesis . When indication antifungal therapy HIV-infected patient , temporal replacement ritonavir posaconazole would attractive option combine treatment HIV fungal infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Subject least 18 old 55 year age day first dose . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior first dose . Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject able willing sign Informed Consent Form prior screen evaluation . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior first dose . Subject normal blood pressure pulse rate , accord Investigator 's judgement . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV test . Positive hepatitis B C test . Pregnant female ( confirm HCG test perform less 4 week first dose ) breastfeed female . Therapy drug ( two week precede dose ) , except paracetamol . Subjects ECG QTc interval great 450 m men , great 470 ms woman screen . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose . Donation blood within 60 day prior first dose . Febrile illness within 3 day first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>boost</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>safety</keyword>
</DOC>